At this year's Euro PCR 2023, the results of two percutaneous renal artery denervation (RDN) studies from China were presented in the "Late Breaking Clinical Trail" session, which aroused heated debates in both academia and the industry: one of them is the "Pivotal Trial of Targeted Denervation for Hypertension" led by Professor Huo Yong of Peking University First Hospital and supported by Suzhou Xinmai Medical Device Co. (hereinafter referred to as "SMART Trial") led by Prof. Huo Yong from Peking University First Hospital and supported by Suzhou Xinmai Medical Devices Co. Ltd. (hereinafter referred to as "Miliweiye") supported the clinical trial "Effectiveness and Safety Study of Netrod-HTN Radiofrequency Denervation System". Both trials received considerable attention, and the results of the studies were positive, providing new evidence for the treatment of hypertension with RDN. The results were deemed positive because, based on the data reported by the investigators, both clinical trials met both the primary and secondary objectives of the study hypotheses. Based on the data reported by the two trials at the conference, on 29 June 2023, industry consultant CIC Consulting led the successful online live streaming of the "SMART Trial Results Interpretation Conference". The meeting was hosted by CIC Consulting, which provided an excellent sharing and interpretation of the differences between the two trials, from protocol design to clinical implementation to data collection, which are worth exploring and thinking about in depth.
Jun 29, 2023